Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2003

View Archived Issues

New antidiabetic agents discovered by Indian researchers

Cytokine production inhibitors prepared and tested at Sankyo

Boehringer Ingelheim describes the preparation and use of epoxide hydrolase inhibitors

Novel integrin antagonists and their use reported by Bayer

Takeda scientists prepare CXCR4 antagonists for AIDS and cancer

Recent Bayer patent covers new guanylate cyclase activators

New distribution agreements for Foscan in East Europe and Mediterranean

Long-term inhibition of bone and joint damage in RA patients on Enbrel

NicVAX phase I/II trial begins enrollment

GPC Biotech licenses intellectual property for use with Reverse Genomics platform

DOR BioPharma to license intranasal vaccine technology from U.K.'s Ministry of Defence

Valentis licenses PEGylation technology to Prolong Pharmaceuticals

Axonyx plans to begin two Alzheimer's trials for phenserine in 2003

Clinical trial of Ono insulin sensitizer halted

Licensing opportunity from the NIH: new mouse model for osteoarthritis

NIH offers ligands for FPR receptors that inhibit HIV infection, boost immune response to microbes

AHCD may be reversible after liver transplant; possible role for immunophilin ligands

Members of the quinoline-indole class of antibacterial agents characterized in further detail

AstraZeneca launches Crestor in Canada

Delay announced in European approval for Amevive

Sonic hedgehog protein demonstrates efficacy in diabetic neuropathy

NS-1209 enters phase II for epilepsy

Newly discovered anti-MRSA antibiotic produced by marine bacterium

Acetylcholinesterase inhibitors related to galanthamine claimed by Sankyo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...